• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
Grand Rounds

Are Optimal Doses of Heart Failure Medications the Same for Men and Women?

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • Medications for heart failure with reduced ejection fraction (HFrEF) include
    • Angiotensin-converting-enzyme (ACE) inhibitors | Angiotensin-receptor blockers (ARBs) | β blockers
    • Men and women are prescribed the same doses
  • Santema et al. (Lancet, 2019) investigated whether there are sex differences in the optimal doses of these medications for HFrEF

METHODS:

  • Post-hoc analysis of prospective BIOSTAT-CHF study (11 European countries)
    • Study to evaluate heart failure treatment with left ventricular ejection fraction less than 40%
    • Findings were validated in ASIAN-HF, an independent cohort of 3539 men and 961 women with HFrEF
  • Primary outcome
    • A composite of time to all-cause mortality or hospitalization for heart failure

RESULTS:

  • 1,308 men and 402 women
  • Women were
    • Older (74 vs 70 years; p<0.0001)
    • Lower bodyweights (72 kg vs 85 kg; p<0.0001)
    • Heights (162 cm vs 174 cm; p<0.0001)
    • No difference in BMI
  • A similar number of men and women reached guideline-recommended target doses
  • Sex differences related to drug dosage and risk for death or hospitalizations for heart failure
    • Men: Lowest numbers of death or hospitalizations for heart failure occurred at 100% of the recommended medication dose
    • Women: 30% lower risk of death or hospitalizations at only 50% of the recommended doses and no further decrease in risk at higher dose levels
    • Adjusting for age and body surface area did not alter results
    • Findings were similar in the second ASIAN-HF study

CONCLUSION:

  • Women may require half the dose of heart failure medications compared to men
  • This finding is particularly important as literature demonstrates that women may have more adverse drug reactions and these reactions may be more severe than those seen in men
  • This study highlights the pervasive bias towards male-based medical guidelines in research and in addition the authors state

This study also underlines the importance of performing prespecified sex-specific analyses in all drug trials

Learn More – Primary Sources:

Identifying optimal doses of heart failure medications in men compared with women: a prospective, observational, cohort study

Now You Can Get ObG Clinical Research Summaries Direct to Your Phone, with ObGFirst

Learn More  »

image_pdfFavoriteLoadingFavorite
< Previous
All Grand Rounds Posts
Next >

Related ObG Topics:

The VIRGO Study Results: In Younger Individuals, Does Heart Attack Presentation Differ Between Women and Men?
Results from the WISE-CVD study: What Can Myocardial Scar Patterns Tell Us About Risk of Serious Cardiac Events in Women?
Does Oxygen Therapy Really Help During a Suspected Heart Attack?

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Download Your ObG App
HERE!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site